Belatacept for maintenance immunosuppression in lung transplantation

Christine Hui, Ryan Kern, David Wojciechowski, Jasleen Kukreja, Jeffrey A. Golden, Steven R. Hays, Jonathan P. Singer

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Belatacept is a novel immunosuppressant that blocks a T-cell costimulation pathway and is approved for use in adult kidney transplant recipients. Its safety and efficacy have not been established after lung transplantation. We present a case of a lung transplant recipient treated with belatacept. A 56-year-old man underwent bilateral lung retransplantation for bronchiolitis obliterans syndrome (BOS). In the third year posttransplant, he developed hemolytic uremic syndrome (HUS) attributed to tacrolimus. Tacrolimus was changed to sirolimus. One month later, he presented with worsening renal function and HUS attributed to sirolimus. Plasmapheresis and steroid pulse were initiated with clinical improvement, and sirolimus was switched to belatacept. He experienced no episodes of cellular rejection but developed recurrent BOS. Complications during treatment included anemia and recurrent pneumonias. The safety and efficacy of belatacept in lung transplantation remains unclear; further studies are needed.

Original languageEnglish (US)
JournalJournal of Investigative Medicine High Impact Case Reports
Volume2
Issue number3
DOIs
StatePublished - 2014

Keywords

  • Belatacept
  • Lung transplant
  • Novel immunosuppression
  • Outcomes

ASJC Scopus subject areas

  • Epidemiology
  • Safety, Risk, Reliability and Quality
  • Safety Research

Fingerprint Dive into the research topics of 'Belatacept for maintenance immunosuppression in lung transplantation'. Together they form a unique fingerprint.

  • Cite this